As one of the first companies to translate microbiome science into novel probiotic therapeutics, Winclove Probiotics regularly achieves breakthroughs in microbiota-management research and probiotic formulations.
We have over 25 years of experience in developing, producing and testing probiotic formulations in collaboration with leading research institutes and academic hospitals. Our large collection of over 100 well-characterized different probiotic strains enables us to explore a wide range of therapeutic indications.
Currently, we are involved in several large scientific projects with both research partners and commercial partners. A few examples:
- Prevention of allergy; (PANDA) study; together with the Wilhelmina Children's Hospital and Wageningen University.
- Prevention of antibiotic-associated diarrhoea; in cooperation with the Maastricht UMC+.
- Extension of the remission time in inflammatory bowel disease (IBD, including Crohn’s disease and ulcerative colitis); in cooperation with Maastricht UMC+ and Linköping University Hospital.
- Reduction of symptoms in constipation; together with the Amsterdam Medical Centre.
We are always looking for scientific partners to join us in exploring host-microbiome interactions and developing novel technologies for a range of diseases. Feel free to contact us if you are interested in setting up collaborative research.